|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/519 | (2006.01) |
| A61K 31/519 | (2013.01) | ||
| A61K 31/506 | (2006.01) | ||
| A61P 9/12 | (2018.01) | ||
| A61P 11/00 | (2006.01) | ||
| A61P 11/00 | (2018.01) | ||
| A61P 9/12 | (2006.01) | ||
| A61K 31/506 | (2013.01) |
| (11) | Number of the document | 3804724 |
| (13) | Kind of document | T |
| (96) | European patent application number | 20203847.7 |
| Date of filing the European patent application | 2017-10-09 | |
| (97) | Date of publication of the European application | 2021-04-14 |
| (45) | Date of publication and mention of the grant of the patent | 2022-12-07 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201662410566 P | 2016-10-20 | US | |
| 201762548629 P | 2017-08-22 | US |
| (72) |
EVANS, Steve Martin , US
|
| (73) |
Pfizer Inc. ,
66 Hudson Boulevard East, New York, NY 10001-2192,
US
|
| (54) | CDK INHIBITORS FOR TREATING PAH |
| CDK INHIBITORS FOR TREATING PAH |